Jakai McEwen, DO
Neurology · Smyrna, GANPI 1649634015
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,343 of the $56,190 with a category attached, or 68.2%. 33 manufacturers reported payments, led by Genentech USA, Inc. at 47.9% of the total. Reporting peaked in 2024 at $18,677 and has fallen 59.8% since, to $7,517 in 2025. Among neurology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $227.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$27K
- EMD Serono, Inc.$14K
- Amgen$8K
- Genentech, Inc.$3K
- Sanofi$953
- Novartis$639
- plus $3K from 27 others
What the payments were for
- Consulting fees$38,34368%
- Speaking & faculty fees$5,1009%
- Travel & lodging$4,0647%
- Food & beverage$8,60615%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 32 | $26,897 |
| EMD Serono, Inc. | 40 | $14,206 |
| Amgen(2 entities) | 38 | $7,879 |
| Genentech, Inc. | 9 | $2,594 |
| Sanofi | 12 | $953 |
| Novartis | 14 | $639 |
| TG Therapeutics, Inc. | 14 | $576 |
| AstraZeneca | 11 | $333 |
| Lilly USA, LLC | 9 | $249 |
| Bristol Myers Squibb | 4 | $216 |
| Biogen | 6 | $208 |
| AbbVie | 8 | $182 |
| Amneal Pharmaceuticals LLC | 5 | $159 |
| Acorda Therapeutics, Inc | 2 | $127 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $113 |
| Johnson & Johnson | 4 | $109 |
| Teva Pharmaceuticals USA, Inc. | 6 | $100 |
| Avanir Pharmaceuticals, Inc. | 5 | $84 |
| Argenx US, Inc. | 3 | $77 |
| ANI Pharmaceuticals, Inc. | 3 | $73 |
| UCB, Inc. | 3 | $59 |
| Grifols USA, LLC | 3 | $56 |
| Pfizer | 2 | $47 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Aucta Pharmaceuticals, Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $30 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Impel Pharmaceuticals LLC | 1 | $20 |
| Harmony Biosciences LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Adamas Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,190 in reported general payments places this provider in the 90th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 72 | $110,851 |
| QuliptaAtogepant | 61 | $71,758 |
| NuplazidPimavanserin Tartrate | 11 | $54,745 |
| Nurtec OdtRimegepant Sulfate | 32 | $51,045 |
| Aimovig AutoinjectorErenumab-Aooe | 40 | $31,986 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 35 | $26,088 |
| BotoxOnabotulinumtoxina | 19 | $21,497 |
| Emgality PenGalcanezumab-Gnlm | 21 | $14,261 |
| RytaryCarbidopa/Levodopa | 13 | $12,141 |
| Ajovy SyringeFremanezumab-Vfrm | 13 | $8,710 |
| Memantine Hcl | 139 | $5,711 |
| Levetiracetam | 122 | $2,857 |
| Pyridostigmine Bromide | 23 | $2,529 |
| Donepezil Hcl | 274 | $2,442 |
| Carbamazepine ErCarbamazepine | 17 | $2,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $182 | $204,106152 claims |
| Acadia Pharmaceuticals IncNuplazid | $42 | $54,74511 claims |
| PfizerNurtec Odt | $47 | $51,04532 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $159 | $14,67036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 506 neurology providers in Georgia.
Other neurology in Smyrna
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
- Dinesh RajuLawrenceville$414K
- Victor RosenfeldSavannah$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.